Wall Street Zen lowered shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) from a hold rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.
Separately, Weiss Ratings cut shares of Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $13.50.
Check Out Our Latest Research Report on Acrivon Therapeutics
Acrivon Therapeutics Price Performance
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. As a group, research analysts anticipate that Acrivon Therapeutics will post -1.76 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Acrivon Therapeutics news, CEO Peter Blume-Jensen sold 14,036 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total transaction of $31,019.56. Following the completion of the sale, the chief executive officer directly owned 2,230,052 shares in the company, valued at approximately $4,928,414.92. The trade was a 0.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 18,253 shares of company stock worth $38,850. 10.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Acrivon Therapeutics
An institutional investor recently bought a new stake in Acrivon Therapeutics stock. Spark Investment Management LLC purchased a new stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 28,300 shares of the company’s stock, valued at approximately $50,000. Spark Investment Management LLC owned approximately 0.07% of Acrivon Therapeutics at the end of the most recent reporting period. Institutional investors own 71.62% of the company’s stock.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with cancer. The company uses its Acrivon Predictive Precision Oncology platform to identify drug candidates and match them with tumor characteristics that may predict treatment response.
Acrivon’s lead investigational product is ACR-368, also known as prexasertib, a small-molecule inhibitor designed to target checkpoint kinase 1 and related cancer cell-cycle mechanisms.
Read More
- Five stocks we like better than Acrivon Therapeutics
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
